Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 90 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Oral Ulcer Clear all
Completed No phase listed Observational Accepts healthy volunteers

The Molecular Anatomy of Oral Wound Healing

NCT01078467
View directory record Official record
Conditions
Wounds and Injuries, Wound Healing, Ulcer
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 40 Years · Male only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Jul 21, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Orally Administered BBT-401-1S in Subjects With Ulcerative Colitis

NCT04596293
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
BBT-401-1S or Placebo
Drug
Lead sponsor
Bridge Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Little Rock, Arkansas • Fountain Valley, California • Lancaster, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Jul 21, 2026, 7:42 PM EDT
Completed No phase listed Observational

Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making

NCT03239834
View directory record Official record
Conditions
Palatal Neoplasms, Lip Neoplasm, Gingival Neoplasms, Leukoplakia, Oral, Tongue Neoplasms, Oropharyngeal Neoplasms, Oral Ulcer
Interventions
OncAlert
Device
Lead sponsor
Vigilant Biosciences, Inc.
Industry
Eligibility
23 Years and older
Enrollment
893 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
26
States / cities
Beverly Hills, California • La Mesa, California • Loma Linda, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Jul 21, 2026, 7:42 PM EDT
Recruiting Phase 2 Interventional

Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis

NCT04373473
View directory record Official record
Conditions
Adults With Ulcerative Colitis
Interventions
PRIM-DJ2727, Placebos
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 21, 2026, 7:42 PM EDT
Recruiting No phase listed Observational

Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders

NCT07683104
View directory record Official record
Conditions
Trisomy 8 Mosaicism, Trisomy 8 Associated Autoinflammatory Disease, Mucosal Ulcerations
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 99 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2056
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 21, 2026, 7:42 PM EDT
Completed No phase listed Observational

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

NCT03941184
View directory record Official record
Conditions
SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
114 participants
Timeline
1995 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 21, 2026, 7:42 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

NCT05076175
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Ozanimod
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
36
States / cities
Phoenix, Arizona • Tucson, Arizona • Garden Grove, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 21, 2026, 7:42 PM EDT
Terminated Phase 2 Interventional Results available

Open-Label Study of Oral Treprostinil in Digital Ulcers

NCT00848107
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
treprostinil diethanolamine
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Jul 21, 2026, 7:42 PM EDT
Completed Phase 3 Interventional Results available

ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients

NCT03689712
View directory record Official record
Conditions
Oral Mucositis
Interventions
GC4419 90mg, Placebo
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
86
States / cities
Gilbert, Arizona • Jonesboro, Arkansas • Corona, California + 77 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Jul 21, 2026, 7:42 PM EDT
Completed Phase 3 Interventional

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

NCT00563433
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
ofloxacin, MSI-78
Drug
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1996
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Jul 21, 2026, 7:42 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

NCT04254783
View directory record Official record
Conditions
Ulcerative Colitis (UC), Crohn's Disease
Interventions
Risankizumab, Cytochrome P450 (CYP) Substrates
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Coronado, California • DeLand, Florida • Margate, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Jul 21, 2026, 7:42 PM EDT
Completed Phase 1Phase 2 Interventional

Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology

NCT03366142
View directory record Official record
Conditions
LAD1
Interventions
Ustekinumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Jul 21, 2026, 7:42 PM EDT
Completed Not applicable Interventional Results available

Impact of Omega-3 Fatty Acid Oral Therapy on Healing of Chronic Venous Leg Ulcers in Older Adults

NCT03576989
View directory record Official record
Conditions
Chronic Venous Leg Ulcers
Interventions
EPA+DHA, placebo
Dietary Supplement · Other
Lead sponsor
Ohio State University
Other
Eligibility
55 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 21, 2026, 7:42 PM EDT
Not listed No phase listed Observational

A Subjective Observational Study of Patients Using Medicated Footbath/Footwash Treatment in Podiatry Care

NCT03781024
View directory record Official record
Conditions
Toenail Fungal Infection, Cellulitis, Pitted Keratolysis, Diabetic Foot Ulcer, Abscess
Interventions
Footwash
Combination Product
Lead sponsor
Data Collection Analysis Business Management
Other
Eligibility
Not listed
Enrollment
5,000 participants
Timeline
2018 – 2022
U.S. locations
1
States / cities
Land O' Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Jul 21, 2026, 7:42 PM EDT
Completed Phase 2 Interventional

Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection

NCT00000790
View directory record Official record
Conditions
HIV Infections, Stomatitis, Aphthous
Interventions
Thalidomide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 21, 2026, 7:42 PM EDT
Recruiting Phase 2 Interventional

Coconut Oil to Prevent Mouth Sores in Pediatric Patients Receiving High Dose Chemotherapy

NCT05441813
View directory record Official record
Conditions
Oral Mucositis
Interventions
Virgin Coconut Oil
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
7 Years to 26 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 21, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Green Tea Extract (Polyphenon E®)in Ulcerative Colitis

NCT00718094
View directory record Official record
Conditions
Mild to Moderately Active Ulcerative Colitis
Interventions
Polyphenon E®, Placebo Oral Tablet
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Jul 21, 2026, 7:42 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

NCT02435992
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
RPC1063, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
113
States / cities
Sun City, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 87 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Jul 21, 2026, 7:42 PM EDT
Completed Phase 4 Interventional Results available

Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)

NCT00446849
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
MMX Mesalamine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
62
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Long Beach, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Jul 21, 2026, 7:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis

NCT01582880
View directory record Official record
Conditions
Chemical Injuries, Unspecified Complication of Corneal Transplant, Autoimmune Diseases, Ocular Cicatricial Pemphigoid, Stevens Johnson Syndrome, Lupus Erythematosus, Systemic, Rheumatoid Arthritis, Other Autoimmune Diseases
Interventions
Riboflavin
Drug
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2019 · Synced Jul 21, 2026, 7:42 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis

NCT01465763
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
tofacitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
71
States / cities
Mobile, Alabama • La Jolla, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Jul 21, 2026, 7:42 PM EDT
Active, not recruiting Phase 2 Interventional

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

NCT06254950
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
TAK-279, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Los Angeles, California • Murrieta, California • Clearwater, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 21, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Oral BT-11 in Ulcerative Colitis

NCT03861143
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
BT-11 (440 mg), BT-11 (880 mg), Placebo
Drug
Lead sponsor
NImmune Biopharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Los Angeles, California • Ventura, California • Walnut Creek, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Jul 21, 2026, 7:42 PM EDT
Completed Phase 2 Interventional

The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid

NCT00001191
View directory record Official record
Conditions
Gastrinoma, Zollinger Ellison Syndrome
Interventions
Pantoprazole, Omeprazole
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1983 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 7:42 PM EDT